Volume 45 Issue 12, December 2024

Cover Credit: Diagram of the proposed mechanisms by which CEMIP reduces the chemotherapy sensitivity of SCLC cells. CEMIP, an adaptor protein, interacts with SRC and YAP. CEMIP binds to SRC, allowing autophosphorylation of Y416 and activation of SRC, which facilitates the interaction between YAP and activated SRC, resulting in increased phosphorylation of Y357, protein stability, nuclear accumulation and transcriptional activation of YAP,thus reducing the chemotherapeutic sensitivity of SCLC cells. The SRC inhibitor dasatinib and the YAP inhibitor verteporfin display synergistic antitumor effects on SCLC both in vitro and in vivo. (DOI 10.1038/s41401-024-01342-4). See the article in pages 2657–2671